Autologous stem cell tranplant in multiple sclerosis leads to extensive renewal of the T cell repertoire

February 19, 2014

(Medical News Today) – A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes. n the Immune Tolerance Network’s (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord.